ARCHIVES

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

This article is from The Cancer Letter archive.

Vol. 33 No. 29 | July 27, 2007

Download PDF Visit The Full Archive

Related Articles

U.S., Canada Begin ExCel Trial To Evaluate Aromasin For Breast Cancer Prevention

April 29, 2005

FDA Tightens Conflict of Interest Rules For Advisors.

March 23, 2007

Court Orders NIH To Retract Electronic Annotations On Fisher Publications

March 24, 1995

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

November 26, 2010

NCI Begins Latin American Cancer Research Network

April 10, 2009

HEW Says Patent Delays Temporary

August 25, 1978